Tokyo - Delayed Quote • JPY
Kobayashi Pharmaceutical Co., Ltd. (4967.T)
At close: April 26 at 3:15 PM GMT+9
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
173,455,000.00
173,455,000.00
166,258,000.00
155,252,000.00
150,514,000.00
Cost of Revenue
77,079,000.00
77,079,000.00
73,927,000.00
66,478,000.00
65,248,000.00
Gross Profit
96,375,000.00
96,375,000.00
92,331,000.00
88,773,000.00
85,265,000.00
Operating Expense
70,591,000.00
70,591,000.00
65,657,000.00
62,702,000.00
59,316,000.00
Operating Income
25,784,000.00
25,784,000.00
26,674,000.00
26,071,000.00
25,949,000.00
Net Non Operating Interest Income Expense
185,000.00
185,000.00
67,000.00
113,000.00
258,000.00
Pretax Income
27,559,000.00
27,559,000.00
27,950,000.00
27,636,000.00
26,635,000.00
Tax Provision
7,221,000.00
7,221,000.00
7,927,000.00
7,920,000.00
7,430,000.00
Net Income Common Stockholders
20,338,000.00
20,338,000.00
20,022,000.00
19,715,000.00
19,205,000.00
Diluted NI Available to Com Stockholders
20,338,000.00
20,338,000.00
20,022,000.00
19,715,000.00
19,205,000.00
Basic EPS
275.75
268.16
259.63
252.36
245.71
Diluted EPS
275.71
268.16
259.59
252.36
245.71
Basic Average Shares
76,210.75
75,842.00
77,122.00
78,125.00
78,163.00
Diluted Average Shares
76,210.75
75,842.00
77,129.32
78,125.00
78,163.00
Total Operating Income as Reported
25,780,000.00
25,780,000.00
26,669,000.00
26,065,000.00
25,943,000.00
Rent Expense Supplemental
1,521,000.00
1,521,000.00
1,462,000.00
1,363,000.00
1,321,000.00
Total Expenses
147,670,000.00
147,670,000.00
139,584,000.00
129,180,000.00
124,564,000.00
Net Income from Continuing & Discontinued Operation
20,338,000.00
20,338,000.00
20,022,000.00
19,715,000.00
19,205,000.00
Normalized Income
20,281,175.51
20,281,175.51
20,375,178.50
20,066,706.20
20,087,557.54
Interest Income
214,000.00
214,000.00
85,000.00
131,000.00
279,000.00
Interest Expense
29,000.00
29,000.00
18,000.00
18,000.00
21,000.00
Net Interest Income
185,000.00
185,000.00
67,000.00
113,000.00
258,000.00
EBIT
27,588,000.00
27,588,000.00
27,968,000.00
27,654,000.00
26,656,000.00
EBITDA
33,645,000.00
33,645,000.00
33,326,000.00
32,489,000.00
30,762,000.00
Reconciled Cost of Revenue
77,079,000.00
77,079,000.00
73,927,000.00
66,478,000.00
65,248,000.00
Reconciled Depreciation
6,057,000.00
6,057,000.00
5,358,000.00
4,835,000.00
4,106,000.00
Net Income from Continuing Operation Net Minority Interest
20,338,000.00
20,338,000.00
20,022,000.00
19,715,000.00
19,205,000.00
Total Unusual Items Excluding Goodwill
77,000.00
77,000.00
-493,000.00
-493,000.00
-1,224,000.00
Total Unusual Items
77,000.00
77,000.00
-493,000.00
-493,000.00
-1,224,000.00
Normalized EBITDA
33,568,000.00
33,568,000.00
33,819,000.00
32,982,000.00
31,986,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
20,175.51
20,175.51
-139,821.50
-141,293.80
-341,442.46
12/31/2020 - 1/4/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade